NCT05827471Not yet recruiting
Clinical Study of QSOX1 as a Biomarker for Colon Cancer
Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer
Source: ClinicalTrials.gov · Last updated 25 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 26 Mar 2023
- Start date
- 1 Jul 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Qianfoshan Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT05827471
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Jul 2023 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp.
- Other tumors other than colon cancer.
Who the study is looking for
- Colon cancer was confirmed by colonoscopic pathology.
- No local or systemic treatment was performed before operation.
- Complete clinical data.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.